Scholar Rock Holding buy Cantor Fitzgerald
Start price
11.12.25
/
50%
€40.40
Target price
11.12.26
-
Performance (%)
-0.99%
Price
12.12.25
€40.00
Summary
This prediction is currently active. Since the start of the prediction for Scholar Rock Holding the price has only changed by -0.99%. This prediction currently runs until 11.12.26. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionScholar Rock is a clinical-stage biopharmaceutical company that engages in the discovery and development of innovative medicines to treat serious diseases in patients that currently have limited or no treatment options. Their pipeline consists of a number of product candidates that target growth factor signaling pathways within the human body. These products hold potential for the treatment of multiple diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock, which trades under the symbol SRRK, is listed on the NASDAQ stock exchange.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Scholar Rock Holding | -0.99% |
| iShares Core DAX® | 0.734% |
| iShares Nasdaq 100 | -2.686% |
| iShares Nikkei 225® | -2.261% |
| iShares S&P 500 | -1.346% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Scholar Rock Holding diskutieren
Scholar Rock (NASDAQ:SRRK) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Ratings data for SRRK provided by MarketBeat